Clinical Trials Search Tool

A Maximum Use (MUsT) Pediatric Study of 1.5% Ruxolitinib Cream in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

Disease/Condition: Atopic Dermatitis

Location: Gresham

Ages: 2-12 years of age

Enrollment Opens: 11-28-2021

Enrollment Closes: TBD


Open-label maximum use trial of ruxolitinib 1.5% cream applied for a
treatment period of 8 weeks followed by an LTS period (44 weeks) and a
30-day safety follow-up period after the last application of study drug. All
participants will apply ruxolitinib 1.5% cream BID during both periods

Study ID: INCB 18424-109

To Enroll: Contact Cyn3rgy Research at; 503-907-2179 ext. 4 or visit us on the web at

Posted by: Cyn3rgy Research |